Mdxhealth's New Share Capital Amount and New Number of Shares
21 10월 2023 - 5:00AM
Mdxhealth's New Share Capital Amount and New Number of Shares
NEWS
RELEASE - REGULATED INFORMATIONOctober 20,
2023, 4:00 PM EDT / 22:00 CET
Mdxhealth's New Share Capital
Amount and New Number of Shares
IRVINE, CA, and HERSTAL,
BELGIUM – October 20, 2023 – MDxHealth SA
(NASDAQ/Euronext: MDXH) ("mdxhealth" or the
"Company"), a commercial-stage precision
diagnostics company, today a announces, in accordance with Article
15 of the Belgian Act of May 2, 2007 on the disclosure of major
participations in issuers of which shares are admitted to trading
on a regulated market and regarding miscellaneous provisions, that
in the context of a capital increase completed on October 20, 2023,
the Company's share capital has increased from
EUR 163,471,629.58 to EUR 164,302,752.89 and the number of
issued and outstanding shares has increased from 270,380,936 to
272,880,936 ordinary shares, through the issuance of a total of
2,500,000 new shares. The new shares were issued pursuant to the
amendment, announced on August 23, 2023, to the asset purchase
agreement for the acquisition by the Company of the Oncotype DX®
GPS (Genomic Prostate Score®) test from Genomic Health, Inc. (a
subsidiary of Exact Sciences Corporation).
In addition to the outstanding shares of the
Company:
- a total of 18,560,124 subscription
rights of the Company are outstanding, which entitles their holders
(assuming all subscription rights are granted and exercised) to
subscribe to a total of 18,560,124 new shares with voting rights;
and
- under the loan and security
agreement entered into by the Company and Innovatus Capital
Partners in August 2022, Innovatus has the right to convert, prior
to August 2, 2025, up to 15% of the outstanding principal amount of
the loans (by means of a contribution in kind of the relevant
payables due by the Company under the loans) into American
Depositary Shares ("ADSs") of the Company (each
representing 10 ordinary shares of the Company) at a conversion
price per ADS equal to USD 11.21 (i.e., USD 1.121 per share on the
basis of the ratio of 1 ADS per 10 shares).
About mdxhealth®
mdxhealth is a commercial-stage precision
diagnostics company that provides actionable molecular information
to personalize patient diagnosis and treatment. The Company’s tests
are based on proprietary genomic, epigenetic (methylation) and
other molecular technologies and assist physicians with the
diagnosis and prognosis of urologic cancers and other urologic
diseases. The Company’s U.S. headquarters and laboratory operations
are in Irvine, California, with additional laboratory operations in
Plano, Texas. European headquarters are in Herstal, Belgium, with
laboratory operations in Nijmegen, The Netherlands. For more
information, visit mdxhealth.com and follow us on social media at:
twitter.com/mdxhealth, facebook.com/mdxhealth and
linkedin.com/company/mdxhealth.
For more information:
mdxhealth info@mdxhealth.com |
|
LifeSci
Advisors (IR & PR)US:
+1-949-271-9223ir@mdxhealth.com |
|
NOTE: The mdxhealth logo,
mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate
Score, GPS and Monitor mdx are trademarks or registered trademarks
of MDxHealth SA. All other trademarks and service marks are the
property of their respective owners.
- MDxHealth - Press Release (ENG)
Mdxhealth (LSE:0O8G)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Mdxhealth (LSE:0O8G)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024